Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
$4.09+9.95%
报价 2026-11-06
市值
$394M
EV
$201.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -41.9%
$3.36$7.04
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZURAZura Bio Limited | $394M | +9.9% | – | 0% | – | – | – | |
| ASMBAssembly Biosciences, Inc. | $415.8M | +2.1% | +57.1% | 72.9% | 54.5x | – | – | |
| SGMTSagimet Biosciences Inc. | $320.9M | +8.0% | -90.0% | 0% | – | – | – | |
| ENTAEnanta Pharmaceuticals, Inc. | $320.4M | +9.1% | -4.7% | 100% | – | – | – | |
| ARCTArcturus Therapeutics Holdings Inc. | $294.2M | +10.6% | -81.3% | 24% | – | – | – | |
| NAUTNautilus Biotechnology, Inc. | $284M | +3.7% | -61.1% | -362.5% | – | – | – | |
| IMRXImmuneering Corporation | $238.3M | +9.2% | +1836.4% | 0% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $111.1M | -1.8% | -18.9% | 42.7% | – | – | – | |
| PYXSPyxis Oncology, Inc. | $105.2M | +3.1% | -100.0% | 99.8% | – | – | – | |
| 同行中位数 | – | – | -40.0% | 33.4% | 54.5x | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。